WO2004096237A3 - Phosphonate analogs for treating metabolic diseases - Google Patents

Phosphonate analogs for treating metabolic diseases Download PDF

Info

Publication number
WO2004096237A3
WO2004096237A3 PCT/US2004/013146 US2004013146W WO2004096237A3 WO 2004096237 A3 WO2004096237 A3 WO 2004096237A3 US 2004013146 W US2004013146 W US 2004013146W WO 2004096237 A3 WO2004096237 A3 WO 2004096237A3
Authority
WO
WIPO (PCT)
Prior art keywords
metabolic diseases
treating metabolic
compounds
phosphonate analogs
phosphonate
Prior art date
Application number
PCT/US2004/013146
Other languages
French (fr)
Other versions
WO2004096237A2 (en
Inventor
James M Chen
Xiaowu Chen
Aesop Cho
Lee S Chong
Maria Fardis
Thorsten A Kirschberg
Steven Krawczyk
Hyung-Jung Pyun
Will Watkins
Original Assignee
Gilead Sciences Inc
James M Chen
Xiaowu Chen
Aesop Cho
Lee S Chong
Maria Fardis
Thorsten A Kirschberg
Steven Krawczyk
Hyung-Jung Pyun
Will Watkins
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc, James M Chen, Xiaowu Chen, Aesop Cho, Lee S Chong, Maria Fardis, Thorsten A Kirschberg, Steven Krawczyk, Hyung-Jung Pyun, Will Watkins filed Critical Gilead Sciences Inc
Publication of WO2004096237A2 publication Critical patent/WO2004096237A2/en
Publication of WO2004096237A3 publication Critical patent/WO2004096237A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking

Abstract

The invention is related to phosphorus substituted compounds with activity for treating metabolic diseases and/or disorders, e.g., diabetes and hypercholesterolemia, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
PCT/US2004/013146 2003-04-25 2004-04-26 Phosphonate analogs for treating metabolic diseases WO2004096237A2 (en)

Applications Claiming Priority (76)

Application Number Priority Date Filing Date Title
US46533903P 2003-04-25 2003-04-25
US46553603P 2003-04-25 2003-04-25
US46531703P 2003-04-25 2003-04-25
US46528603P 2003-04-25 2003-04-25
US46576303P 2003-04-25 2003-04-25
US46568903P 2003-04-25 2003-04-25
US46539903P 2003-04-25 2003-04-25
US46547503P 2003-04-25 2003-04-25
US46535503P 2003-04-25 2003-04-25
US46529203P 2003-04-25 2003-04-25
US46575103P 2003-04-25 2003-04-25
US46532503P 2003-04-25 2003-04-25
US60/465,325 2003-04-25
US60/465,763 2003-04-25
US60/465,536 2003-04-25
US60/465,286 2003-04-25
US60/465,339 2003-04-25
US60/465,355 2003-04-25
US60/465,317 2003-04-25
US60/465,292 2003-04-25
US60/465,751 2003-04-25
US60/465,475 2003-04-25
US60/465,399 2003-04-25
US60/465,689 2003-04-25
US49553103P 2003-08-15 2003-08-15
US49576203P 2003-08-15 2003-08-15
US49536103P 2003-08-15 2003-08-15
US49548903P 2003-08-15 2003-08-15
US49586303P 2003-08-15 2003-08-15
US49553403P 2003-08-15 2003-08-15
US49534703P 2003-08-15 2003-08-15
US49568103P 2003-08-15 2003-08-15
US49575303P 2003-08-15 2003-08-15
US49552603P 2003-08-15 2003-08-15
US49535403P 2003-08-15 2003-08-15
US49566903P 2003-08-15 2003-08-15
US60/495,347 2003-08-15
US60/495,669 2003-08-15
US60/495,753 2003-08-15
US60/495,489 2003-08-15
US60/495,762 2003-08-15
US60/495,863 2003-08-15
US60/495,534 2003-08-15
US60/495,361 2003-08-15
US60/495,531 2003-08-15
US60/495,354 2003-08-15
US60/495,681 2003-08-15
US60/495,526 2003-08-15
US51396603P 2003-10-24 2003-10-24
US51446503P 2003-10-24 2003-10-24
US51395403P 2003-10-24 2003-10-24
US51410403P 2003-10-24 2003-10-24
US51430303P 2003-10-24 2003-10-24
US60/513,966 2003-10-24
US60/514,465 2003-10-24
US60/513,954 2003-10-24
US60/514,303 2003-10-24
US60/514,104 2003-10-24
US53218303P 2003-12-22 2003-12-22
US53227403P 2003-12-22 2003-12-22
US53218403P 2003-12-22 2003-12-22
US53227303P 2003-12-22 2003-12-22
US60/532,274 2003-12-22
US60/532,183 2003-12-22
US60/532,184 2003-12-22
US60/532,273 2003-12-22
US53268203P 2003-12-23 2003-12-23
US53241503P 2003-12-23 2003-12-23
US53258703P 2003-12-23 2003-12-23
US53268303P 2003-12-23 2003-12-23
US60/532,683 2003-12-23
US60/532,415 2003-12-23
US60/532,587 2003-12-23
US60/532,682 2003-12-23
US53617904P 2004-01-12 2004-01-12
US60/536,179 2004-01-12

Publications (2)

Publication Number Publication Date
WO2004096237A2 WO2004096237A2 (en) 2004-11-11
WO2004096237A3 true WO2004096237A3 (en) 2005-04-21

Family

ID=33425960

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/013146 WO2004096237A2 (en) 2003-04-25 2004-04-26 Phosphonate analogs for treating metabolic diseases

Country Status (1)

Country Link
WO (1) WO2004096237A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871785B2 (en) 2003-04-25 2014-10-28 Gilead Sciences, Inc. Antiviral phosphonate analogs
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME01945B (en) 2004-07-27 2011-12-31 Gilead Sciences Inc Nucleoside phosphonate conjugates as anti hiv agents
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
DE102007035333A1 (en) * 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel substituted arylsulfonylglycines, their preparation and their use as pharmaceuticals
DE102007035334A1 (en) * 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel substituted arylsulfonylglycines, their preparation and their use as pharmaceuticals
US8658617B2 (en) 2008-07-08 2014-02-25 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
JP2013523765A (en) 2010-04-01 2013-06-17 イデニク プハルマセウティカルス，インコーポレイテッド Compounds and pharmaceutical compositions for the treatment of viral infections
ITVI20130039A1 (en) 2013-02-20 2014-08-21 F I S Fabbrica Italiana Sint I S P A PROCESS FOR THE PREPARATION OF KEY INTERMEDIATES FOR STATIN SYNTHESIS
CN103570612B (en) * 2013-11-08 2016-01-06 常熟市联创化学有限公司 A kind of preparation method of 6-chlorine apellagrin
EA201891817A1 (en) * 2016-02-11 2019-07-31 Стихтинг Катхолике Юниверситейт NEW CLASS OF COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISEASES
EP3960740B1 (en) 2017-08-01 2023-11-15 Gilead Sciences, Inc. Crystalline forms of ethyl ((s)-((((2r,5r)-5-(6-amino-9h-purin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl)oxy)methyl)(phenoxy)phosphoryl)-l-alaninate (gs-9131) vanillate for treating viral infections
CN113527273B (en) * 2020-10-28 2023-08-22 中国药科大学 Compound for degrading HMGCR in targeted ubiquitination or pharmaceutically acceptable salt thereof, preparation method and application

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000988A1 (en) * 1990-07-13 1992-01-23 Bodor Nicholas S Targeted drug delivery via phosphonate derivatives
WO1993012123A1 (en) * 1991-12-10 1993-06-24 British Bio-Technology Limited 3-carboxy-2-hydroxy-propane-phosphonic acid derivatives
WO2001046204A1 (en) * 1999-12-22 2001-06-28 Merck Frosst Canada & Co. Aromatic phosphonates as protein tyrosine phosphatase 1b (ptp-1b) inhibitors
WO2003090690A2 (en) * 2002-04-26 2003-11-06 Gilead Sciences, Inc. Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds and the compounds as such

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000988A1 (en) * 1990-07-13 1992-01-23 Bodor Nicholas S Targeted drug delivery via phosphonate derivatives
WO1993012123A1 (en) * 1991-12-10 1993-06-24 British Bio-Technology Limited 3-carboxy-2-hydroxy-propane-phosphonic acid derivatives
WO2001046204A1 (en) * 1999-12-22 2001-06-28 Merck Frosst Canada & Co. Aromatic phosphonates as protein tyrosine phosphatase 1b (ptp-1b) inhibitors
WO2003090690A2 (en) * 2002-04-26 2003-11-06 Gilead Sciences, Inc. Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds and the compounds as such

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HIRABAYASHI H. ET AL: "Bone specific drug delivery systems", CLIN PHARMACOKINET, vol. 42, no. 15, 2003, pages 1319 - 1330, XP008037142 *
LEFF T. ET AL.: "The antidiabetic PPARy ligands: an update on compounds in development", CURR MED CHEM. IMUN,ENDOC. AND METAB. AGENTS, 2002, pages 33 - 47, XP008037676 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8871785B2 (en) 2003-04-25 2014-10-28 Gilead Sciences, Inc. Antiviral phosphonate analogs
US9243025B2 (en) 2011-03-31 2016-01-26 Idenix Pharmaceuticals, Llc Compounds and pharmaceutical compositions for the treatment of viral infections

Also Published As

Publication number Publication date
WO2004096237A2 (en) 2004-11-11

Similar Documents

Publication Publication Date Title
WO2004096286A3 (en) Antiviral phosphonate analogs
WO2005002626A3 (en) Therapeutic phosphonate compounds
WO2004096285A3 (en) Anti-infective phosphonate conjugates
UA86614C2 (en) Compound having kinase ingibitor activity, pharmaceutical composition containing thereof and use thereof for the preparation of medicine
NO20055590L (en) Kinase Inhibiting Phosphonate Analogs
WO2006037982A3 (en) Modulators of crth2 receptor activity for the treatment of prostaglandin d2 mediated diseases
EA200701296A1 (en) 3,5-Disposable and 3,5,7-triple-substituted 3H-oxazolo-and 3H-thiazolo [4,5-D] pyrimidin-2-she and their medicines
TW200614996A (en) Antiviral compounds
UA91688C2 (en) Antiviral compounds
WO2001078711A3 (en) Pde-v inhibitors for treatment of parkinson's disease
BRPI0409680A (en) anti-cancer phosphonate analogs
BRPI0409109A (en) new compounds
WO2004096233A3 (en) Nucleoside phosphonate conjugates
WO2004096237A3 (en) Phosphonate analogs for treating metabolic diseases
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
WO2009025785A3 (en) Cb2 receptor ligands for the treatment of pain
HK1079526A1 (en) A novel pyrazine compound and its use in the manufacture of a medicament for treating diseases related to serotonin
ATE389395T1 (en) SUBSTITUTED 2-AMINOTETRALINE FOR THE PREVENTIVE TREATMENT OF PARKINSON'S DISEASE
WO2002057215A3 (en) Sodium channel modulators
WO2004096287A3 (en) Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
MXPA05011294A (en) Anti-inflammatory phosphonate compounds.
EP1441724B8 (en) Methods of increasing endogenous testosterone levels
WO2009148290A3 (en) 3-substituted propanamine compounds
WO2004096236A3 (en) Immunomodulator phosphonate conjugates

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
122 Ep: pct application non-entry in european phase
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)